Moderna announces administration of pediatric COVID-19 vaccine doses

By The Science Advisory Board staff writers

March 16, 2021 -- Moderna announced that the first participants have been dosed in its phase II/III study of its pediatric messenger RNA (mRNA) COVID-19 vaccine candidate, mRNA-1273.

The study, called KidCove, will eventually include 6,750 healthy children between six months and 12 years of age from the U.S. and Canada. It is being conducted in partnership with the U.S. National Institute of Allergy and Infectious Diseases (NIAID) and the Biomedical Advanced Research and Development Authority (BARDA), and will evaluate the safety, tolerability, reactogenicity, and effectiveness of two doses of the vaccine administered 28 days apart.

Moderna also announced that it has begun dosing the first participants in a phase I study evaluating its next generation COVID-19 vaccine, mRNA-1283, a refrigerator-stable mRNA drug that the company hopes will allow for easier distribution and administration, it said.

Moderna doses 1st patients in COVID-19 vaccine booster trial
Moderna has dosed the first patients in its study of modified COVID-19 vaccines, designed to address the potential need for vaccine booster candidates.
Moderna addresses SARS-CoV-2 variants, ramps up vaccine production
Moderna is pursuing two strategies against emerging SARS-CoV-2 variants. The company is evaluating booster vaccine doses and is increasing vaccine manufacturing...
U.S. commits to additional 100M Moderna COVID-19 vaccine doses
The U.S. government has purchased an additional 100 million doses of Moderna's COVID-19 vaccine.
U.S. increases order of Moderna mRNA COVID-19 vaccine to 300M doses
Moderna is in discussion with the U.S. government for the purchase of an additional 100 million doses of its messenger RNA (mRNA) COVID-19 vaccine,...
U.K. authorizes Moderna COVID-19 vaccine
The U.K.'s Medicines and Healthcare products Regulatory Agency approved Moderna's messenger RNA (mRNA) COVID-19 vaccine, mRNA-1273, for use under Regulation...

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter